Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis.

[1]  E. Schwarz,et al.  Reduction of particle-induced osteolysis by interleukin-6 involves anti-inflammatory effect and inhibition of early osteoclast precursor differentiation. , 2009, Bone.

[2]  J. Zwerina,et al.  Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. , 2009, Arthritis and rheumatism.

[3]  D. Burr,et al.  Osteoblast Function Is Compromised at Sites of Focal Bone Erosion in Inflammatory Arthritis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  F. Blanchard,et al.  The dual role of IL-6-type cytokines on bone remodeling and bone tumors. , 2009, Cytokine & growth factor reviews.

[5]  M. Oukka.  Th17 cells in immunity and autoimmunity , 2008, Annals of the rheumatic diseases.

[6]  M. Hashizume,et al.  IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. , 2008, Rheumatology.

[7]  J. David,et al.  The role of Wnt proteins in arthritis , 2008, Nature Clinical Practice Rheumatology.

[8]  C. Bäckesjö,et al.  IL-6 receptor expression and IL-6 effects change during osteoblast differentiation. , 2008, Cytokine.

[9]  Gang Wang,et al.  Expression characteristic and significance of interleukin-6, nuclear factor kappa beta, and bone formation markers in rat models of osteoporosis. , 2008, Translational research : the journal of laboratory and clinical medicine.

[10]  D. Heymann,et al.  Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. , 2008, Endocrinology.

[11]  K. Ishihara,et al.  Interleukin-6 Directly Inhibits Osteoclast Differentiation by Suppressing Receptor Activator of NF-κB Signaling Pathways* , 2008, Journal of Biological Chemistry.

[12]  J. O’Shea,et al.  Cytokine signaling modules in inflammatory responses. , 2008, Immunity.

[13]  N. Pleshko Camacho,et al.  Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. , 2007, Bone.

[14]  D. M. van der Heijde,et al.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.

[15]  P. Miossec,et al.  The role of T cells in rheumatoid arthritis: new subsets and new targets , 2007, Current opinion in rheumatology.

[16]  Georg Schett,et al.  Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.

[17]  T. Kishimoto,et al.  Interleukin 6: from bench to bedside , 2006, Nature Clinical Practice Rheumatology.

[18]  A. Teti,et al.  Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. , 2006, Arthritis and rheumatism.

[19]  T. Kishimoto,et al.  Interleukin-6 : discovery of a pleiotropic cytokine , 2022 .

[20]  P. Lipsky.  Interleukin-6 and rheumatic diseases , 2006, Arthritis research & therapy.

[21]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[22]  S. Goldring,et al.  Rheumatic diseases: the effects of inflammation on bone , 2005, Immunological reviews.

[23]  U. Müller-Ladner,et al.  Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. , 2005, Rheumatology.

[24]  M. Malaise,et al.  Interleukin-6: An osteotropic factor influencing bone formation? , 2005, Bone.

[25]  J. Aubin,et al.  GP130/OSMR is the only LIF/IL‐6 family receptor complex to promote osteoblast differentiation of calvaria progenitors , 2005, Journal of cellular physiology.

[26]  P. Esbrit,et al.  The Interleukin-6/Soluble Interleukin-6 Receptor System Induces Parathyroid Hormone–Related Protein in Human Osteoblastic Cells , 2004, Calcified Tissue International.

[27]  T. Martin,et al.  Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. , 2004, The Journal of clinical investigation.

[28]  S. Rose-John,et al.  Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.

[29]  N. Athanasou,et al.  Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. , 2002, Bone.

[30]  Y. Saeki,et al.  A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis , 2002, The Journal of experimental medicine.

[31]  U. Lerner,et al.  IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.

[32]  C. Benoist,et al.  Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis , 2002, The Journal of experimental medicine.

[33]  John C. Lee,et al.  Osteogenic protein‐1 and interleukin‐6 with its soluble receptor synergistically stimulate rat osteoblastic cell differentiation , 2002, Journal of cellular physiology.

[34]  A R Pettit,et al.  TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.

[35]  C. O’Brien,et al.  Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL‐6‐type cytokines , 2000, Journal of cellular biochemistry.

[36]  D. Heymann,et al.  gp130 Cytokine family and bone cells. , 2000, Cytokine.

[37]  梅下 光子.  Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice , 2000 .

[38]  M. Baiocchi,et al.  Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. , 1999, Cytokine.

[39]  A. Verbruggen,et al.  Flow cytometrical determination of interleukin 1beta, interleukin 6 and tumour necrosis factor alpha in monocytes of rheumatoid arthritis patients; relation with parameters of osteoporosis. , 1999, Cytokine.

[40]  P. Miossec,et al.  Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. , 1999, Arthritis and rheumatism.

[41]  S. C. Lin,et al.  Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. , 1998, Proceedings of the Association of American Physicians.

[42]  G. Kollias,et al.  Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.

[43]  N. Franchimont,et al.  Interleukin-6 with its soluble receptor enhances the expression of insulin-like growth factor-I in osteoblasts. , 1997, Endocrinology.

[44]  U. Müller-Ladner,et al.  Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. , 1997, British journal of rheumatology.

[45]  T. Vischer,et al.  Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. , 1997, The Journal of rheumatology.

[46]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[47]  G. Ciliberto,et al.  Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. , 1997, The Journal of clinical investigation.

[48]  G. Yancopoulos,et al.  Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. , 1996, The Journal of clinical investigation.

[49]  N. Udagawa,et al.  Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  F. Takahashi,et al.  Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. , 1995, The American journal of pathology.

[51]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[52]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[53]  G. Ciliberto,et al.  Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.

[54]  R. Madhok,et al.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. , 1993, Annals of the rheumatic diseases.

[55]  T. Hirano,et al.  Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.

[56]  J. Miyazaki,et al.  IgG1 plasmacytosis in interleukin 6 transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[58]  F. Houssiau,et al.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.

[59]  I. Wicks,et al.  Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. , 2006, Arthritis and rheumatism.

[60]  T. Sugiyama.  Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis , 2001, Journal of Bone and Mineral Metabolism.

[61]  大島 至郎.  Interleukin 6 plays a key role in the development of antigen-induced arthritis , 1999 .

[62]  B. Kirkham,et al.  Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. , 1992, The Journal of rheumatology.